Chronic Lymphocytic Leukemia

Alexey V. Danilov, MD, PhD, discusses the efficacy of entospletinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Optical genome mapping was found to effectively detect most abnormalities defined by standard methods, such as chromosome banding analysis, chromosomal microarrays, and fluorescence in situ hybridization, as well as several additional abnormalities of unknown clinical significance, in patients with chronic lymphocytic leukemia.

The use of a cell-free DNA–based minimal residual disease assay demonstrated feasibility and highly concordant results compared with 4-color flow cytometry and improved MRD detection in patients with chronic lymphocytic leukemia who were treated with time-limited venetoclax, acalabrutinib, and obinutuzumab.

CRISPR/Cas9 and mRNA-based gene editing and expression was found to be feasible in evaluating primary chronic lymphocytic leukemia cells.

COVID-19 continued to result in high admission and fatality rates among patients with chronic lymphocytic leukemia during the first 13 months of the pandemic, and although risk of severe infection was determined to be independent of age, CLL status, and treatment, being age 75 years or older was revealed to be a significant risk factor for death.

H3B-8800, a splicing molecule that binds to Splicing Factor 3b Subunit 1, has been shown to delay leukemic infiltration in a model of chronic lymphocytic leukemia using NOD-SCID interleukin-2 receptor gamma mice.

Catherine Callaghan Coombs, MD, discusses the rationale for the BRUIN study, key efficacy and safety findings, and next steps with pirtobrutinib in chronic lymphocytic leukemia.

John C. Byrd, MD, discusses key findings from ELEVATE-RR, differences between acalabrutinib and ibrutinib, and future directions with the second-generation inhibitor.

Alexey V. Danilov, MD, PhD, discusses the need to identify novel pathways for targeted therapy in chronic lymphocytic leukemia.

Sitting at the forefront of clinical development, pirtobrutinib and lisocabtagene maraleucel have generated significant enthusiasm in chronic lymphocytic leukemia.

Patients with chronic lymphocytic leukemia are at an increased risk for infection whether they are in the premalignant state of monoclonal B lymphocytosis, during active surveillance for those are treatment naïve, or are on active treatment.

Pirtobrutinib, showcased promising efficacy signals across dose levels in previously treated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Catherine Callaghan Coombs, MD, discusses the efficacy results of the ongoing phase 1/2 BRUIN study with pirtobrutinib in chronic lymphocytic leukemia.

Alexey V. Danilov, MD, PhD, discusses the utility of BTK inhibitors as a treatment option for patients with chronic lymphocytic leukemia.

An expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.

Experts discuss emerging agents for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Ehab L. Atallah, MD, discusses the prognostic role of undetectable minimal residual disease in chronic lymphocytic leukemia.

An overview of data for PI3K inhibitors for in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Experts in chronic lymphocytic leukemia (CLL) discuss retreating patients with venetoclax.

Considerations for the future treatment landscape of relapsed/refractory CLL, in light of emerging practices and clinical trial data.

Experts detail optimal sequencing strategies when patients with relapsed/refractory CLL move on to the next line of therapy.

An in-depth analysis of current therapeutic options in relapsed/refractory chronic lymphocytic leukemia.

A discussion about treatment for high-risk patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Nicole Lamanna, MD, provides an overview of Bruton's tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL) in the relapsed/refractory (R/R) setting.

Key opinion leaders look forward to upcoming improvements in the frontline management of chronic lymphocytic leukemia.

Experts reflect on core decisions inherent in selecting frontline therapy for patients with CLL, specifically regarding the use of BTK inhibitors, BCL2 inhibitors, anti-CD20 agents, and chemoimmunotherapy.

An expert hematologist/oncologist highlights key takeaways for the future management of chronic lymphocytic leukemia given an evolving therapeutic landscape.

Practical advice on optimal toxicity management and sequencing of therapy in patients with chronic lymphocytic leukemia.

Tara Graff, DO, MS, reflects on the head-to-head comparison data of acalabrutinib vs ibrutinib in patients with previously treated CLL.

Expert insight on the use of frontline BTK inhibitor monotherapy over combination therapy in CLL regarding the ELEVATE-TN trial’s readout.